Cobalt-Doped Carbon Quantum Dots Work Synergistically with Weak Acetic Acid to Eliminate Antimicrobial-Resistant Bacterial Infections
Source abstract
Abstract
When pathogenic bacteria colonize a wound, they can create an alkaline ecological niche that selects for their survival by creating an inflammatory environment restricting healthy wound healing to proceed. To aid healing, wound acidification has been exploited to disrupt this process and stimulate fibroblast growth, increase wound oxygen concentrations, minimize proteolytic activity, and restimulate the host immune system. Within this study, we have developed cobalt-doped carbon quantum dot nanoparticles that work together with mild acetic acid, creating a potent synergistic antimicrobial therapy. The acidic environment alters the osmotic balance of microorganisms, forcing them to swell and speed up the internalization of the ultrasmall particles. The particles hyperpolarize the bacterial membranes and generate damaging peroxidase species, resulting in cellular lysis. In mice, cobalt-doped carbon quantum dots remove MRSA infection while allowing wounds to heal at rates equivalent to that of uninfected wounds. This work demonstrates how synergistic antimicrobial treatment strategies can be successfully used to combat antimicrobial-resistant infections.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Carbon and Quantum Dots Applications · Graphene and Nanomaterials Applications · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biomedicine
University of Bergen
Flinders Institute for Nanoscale Science and Technology, College of Science and Engineering
Flinders University
Department of Biochemistry and Biophysics
University of California
Department of Urology
Helen Diller Family Comprehensive Cancer Center
Bakar Computational Health Sciences Institute
Cancer Research Program
QIMR Berghofer Medical Research Institute
Funding
The General Medical Research Fund · Familien Blix Fond
References (56)
Show source-provided references
1. WHO. 2023 Antibacterial Agents in Clinical and Preclinical Development: An Overview and Analysis; World Health Organization: Geneva, 2024; Licence: CC BY-NC-SA 3.0 IGO.
2. 10.1016/s2666-5247(22)00303-210.1016/s2666-5247(22)00303-2 ↗
3. 10.1021/acs.accounts.3c0045910.1021/acs.accounts.3c00459 ↗
4. 10.1038/s41467-022-33474-810.1038/s41467-022-33474-8 ↗
5. 10.1038/s41551-020-0540-y10.1038/s41551-020-0540-y ↗
6. 10.1126/sciadv.adn789610.1126/sciadv.adn7896 ↗
7. 10.1002/smll.20220575410.1002/smll.202205754 ↗
8. 10.1002/advs.20220125410.1002/advs.202201254 ↗
9. Schultz G. S. · 2011
10. 10.1038/nrmicro95510.1038/nrmicro955 ↗
11. 10.1002/advs.20220125410.1002/advs.202201254 ↗
12. 10.1126/sciadv.abj015310.1126/sciadv.abj0153 ↗
13. 10.1016/j.bios.2012.09.02910.1016/j.bios.2012.09.029 ↗
14. 10.1111/wrr.1212510.1111/wrr.12125 ↗
15. 10.3390/diagnostics1002010710.3390/diagnostics10020107 ↗
16. 10.4103/ijps.IJPS_245_1610.4103/ijps.IJPS_245_16 ↗
17. 10.1016/j.burns.2008.11.00910.1016/j.burns.2008.11.009 ↗
18. 10.1186/s12866-022-02716-610.1186/s12866-022-02716-6 ↗
19. 10.1016/s0140-6736(68)90004-410.1016/s0140-6736(68)90004-4 ↗
20. 10.1097/00000658-197312000-0001110.1097/00000658-197312000-00011 ↗
21. 10.1002/advs.20210500810.1002/advs.202105008 ↗
22. 10.1093/nar/21.17.409310.1093/nar/21.17.4093 ↗
23. 10.1039/D0DT01004A10.1039/D0DT01004A ↗
24. 10.1002/smll.20210634210.1002/smll.202106342 ↗
25. 10.1016/j.chembiol.2023.04.00910.1016/j.chembiol.2023.04.009 ↗
26. 10.1002/adma.20210017610.1002/adma.202100176 ↗
27. 10.1126/sciadv.add928010.1126/sciadv.add9280 ↗
28. 10.3184/00368500378323862610.3184/003685003783238626 ↗
29. 10.1016/j.mib.2020.03.00610.1016/j.mib.2020.03.006 ↗
30. 10.1111/iwj.1242810.1111/iwj.12428 ↗
31. 10.1038/s43246-024-00469-510.1038/s43246-024-00469-5 ↗
32. 10.1126/science.291.5508.154410.1126/science.291.5508.1544 ↗
33. 10.1038/nature0603310.1038/nature06033 ↗
34. 10.1038/s41577-024-01080-y10.1038/s41577-024-01080-y ↗
35. 10.1128/mbio.03443-2010.1128/mbio.03443-20 ↗
36. 10.1186/s13567-023-01200-x10.1186/s13567-023-01200-x ↗
37. 10.1016/j.freeradbiomed.2020.10.32210.1016/j.freeradbiomed.2020.10.322 ↗
38. 10.1016/j.stem.2022.07.00610.1016/j.stem.2022.07.006 ↗
39. 10.1096/fj.201902836r10.1096/fj.201902836r ↗
40. 10.1038/s41467-021-23278-710.1038/s41467-021-23278-7 ↗
41. 10.1002/adhm.20230056810.1002/adhm.202300568 ↗
42. 10.1016/j.pmatsci.2022.10097610.1016/j.pmatsci.2022.100976 ↗
43. 10.1002/asia.20180085110.1002/asia.201800851 ↗
44. 10.1002/sstr.20240037010.1002/sstr.202400370 ↗
45. 10.1002/adfm.20210519810.1002/adfm.202105198 ↗
46. 10.1021/acsnano.5b0206710.1021/acsnano.5b02067 ↗
47. 10.1021/acsnano.4c1389910.1021/acsnano.4c13899 ↗
48. 10.1016/j.jiph.2013.05.00510.1016/j.jiph.2013.05.005 ↗
49. 10.1038/s41429-018-0111-610.1038/s41429-018-0111-6 ↗
50. 10.1007/s12030-009-9029-110.1007/s12030-009-9029-1 ↗
51. 10.1002/adfm.20180586010.1002/adfm.201805860 ↗
52. 10.1016/j.mattod.2013.11.00310.1016/j.mattod.2013.11.003 ↗
53. 10.1016/j.jdermsci.2017.12.00910.1016/j.jdermsci.2017.12.009 ↗
54. 10.1016/j.jgar.2021.05.01010.1016/j.jgar.2021.05.010 ↗
55. 10.1093/bjsopen/zrab12510.1093/bjsopen/zrab125 ↗
56. 10.1093/nar/gkac19410.1093/nar/gkac194 ↗